Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA.
about
Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondDevelopmental origin and lineage plasticity of endogenous cardiac stem cellsMultipotent stem cells of the heart-do they have therapeutic promise?Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarctionMdivi-1 induced acute changes in the angiogenic profile after ischemia-reperfusion injury in female mice.New vessel formation in the context of cardiomyocyte regeneration--the role and importance of an adequate perfusing vasculature.Concise review: tissue-specific microvascular endothelial cells derived from human pluripotent stem cells.Next-generation models of human cardiogenesis via genome editingSynthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine.Insulin-Like Growth Factor 1 Receptor-Dependent Pathway Drives Epicardial Adipose Tissue Formation After Myocardial Injury.Emerging regenerative approaches for periodontal reconstruction: a systematic review from the AAP Regeneration Workshop.Avoiding immunological rejection in regenerative medicine.Efficient delivery and functional expression of transfected modified mRNA in human embryonic stem cell-derived retinal pigmented epithelial cells.Prospects for improving neovascularization of the ischemic heart: Lessons from development.Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease.Tolerance induction to human stem cell transplants with extension to their differentiated progeny.Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences.Individual Variation in Conditional β Cell Ablation Mice Contributes Significant Biases in Evaluating β Cell Functional Recovery.Controlling expansion and cardiomyogenic differentiation of human pluripotent stem cells in scalable suspension culture.Genetic Modification of Human Pancreatic Progenitor Cells Through Modified mRNA.Vascular Development and Regeneration in the Mammalian Heart.Optimizing Cardiac Delivery of Modified mRNA.Engineering Scalable Manufacturing of High-Quality Stem Cell-Derived Cardiomyocytes for Cardiac Tissue Repair.Improvement of vascular dysfunction by argirein through inhibiting endothelial cell apoptosis associated with ET-1/Nox4 signal pathway in diabetic rats
P2860
Q26861563-D9698202-1479-403A-A9A7-DDBF8F3C8F22Q28080127-6E933D52-EE09-4BCE-BBC5-7F6652D08AF7Q28085334-B1DD36C8-7807-4187-AFE2-3836204B09CBQ30580723-A79B0B21-E80F-46D1-AB10-6661BFF3EEBCQ33800230-4E818534-1EB1-477D-9114-CD1D8BC7A77BQ34422460-E8DC3447-BCD5-4A05-81E7-24AF0350D13FQ34577527-B29F06DA-9CFC-4210-8771-1AC0C407A998Q34930371-C52DB340-106C-4289-90C2-82984B6E3FCCQ35319305-C7F7EE7E-4DC4-4B14-9458-E950083669BDQ36179651-56930BB2-1EC9-4FE0-91C8-31043CBAE6FCQ38341431-A0777FB3-1703-40A7-A7A9-B099A47FCC56Q38453650-967C44EC-D411-4881-BD57-36BA459A7F10Q38923727-52A6E73B-99B9-4B2D-BC70-5F8D68AB3E58Q39012408-68B6718E-1B6F-4148-BC21-875915B2ABB9Q39027005-A8A6B7F2-EC9D-4A09-BD18-CA3829DF7BDBQ39092500-320316BC-C88B-4644-975C-161707C62906Q40654970-280B66D2-6A4C-4330-9957-64ADF847FC7CQ41672966-AEEE266D-662B-4D3B-B2F4-61D9BBB55E27Q41779162-5ABF03D1-7197-452F-9E80-0C2320E7A311Q45887525-24038089-602B-4537-96DE-7D1F441234A5Q48678269-E42564F0-E101-4EEF-B8E2-7DC26D8E0CD5Q50445673-933A532D-9CF3-4827-A7E6-E11FA3CFFBD0Q55287570-973A970D-E64D-4FAE-A315-B1E6C564A083Q58722016-24F0ABA2-6FEA-4410-B3F4-6EB103177ED5
P2860
Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Driving vascular endothelial c ...... itors with VEGF modified mRNA.
@en
Driving vascular endothelial c ...... itors with VEGF modified mRNA.
@nl
type
label
Driving vascular endothelial c ...... itors with VEGF modified mRNA.
@en
Driving vascular endothelial c ...... itors with VEGF modified mRNA.
@nl
prefLabel
Driving vascular endothelial c ...... itors with VEGF modified mRNA.
@en
Driving vascular endothelial c ...... itors with VEGF modified mRNA.
@nl
P2093
P2860
P356
P1433
P1476
Driving vascular endothelial c ...... nitors with VEGF modified mRNA
@en
P2093
David J Mooney
Kenneth R Chien
Lior Zangi
Makoto Sahara
Ronald A Li
P2860
P2888
P304
P356
10.1038/CR.2013.112
P577
2013-09-10T00:00:00Z